Search - tctmd.com

Displaying 181 - 200 of 275

Sort: Relevancy | Date

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

News Daily News

Younger Women With STEMI More Likely Than Men to Die In-Hospital

L.A. McKeown

October 28, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

Caitlin E. Cox

September 01, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

Presentation

Use and Outcomes of Triple Therapy Among Older Patients With Acute MI and A-fib

Presenter: Connie N. Hess

August 03, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

Study Suggests Patient Age of 90 Years or More Should Not Preclude TAVR

Todd Neale

July 27, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Daily News

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

L.A. McKeown

July 08, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Knowledge Gaps and Misperceptions on Impact of Atrial Fibrillation and Stroke Exist Among Patients, Caregivers and Physicians

May 13, 2015

News Daily News

A-fib Identified as a Risk Factor for Incident NSTEMI

Todd Neale

May 07, 2015

Advertisement

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Younger Women With STEMI More Likely Than Men to Die In-Hospital

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

NSAIDs Plus Anticoagulants a Bad Combination

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

Use and Outcomes of Triple Therapy Among Older Patients With Acute MI and A-fib

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Study Suggests Patient Age of 90 Years or More Should Not Preclude TAVR

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

UK launch for Daiichi's bloodthinner Lixiana

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Knowledge Gaps and Misperceptions on Impact of Atrial Fibrillation and Stroke Exist Among Patients, Caregivers and Physicians

A-fib Identified as a Risk Factor for Incident NSTEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content